SCHEMBL23915315

SCHEMBL23915315

Nc1cc(Cl)c(OCC(F)(F)F)cc1N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.60
ALDH1A1 P00352 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 2/20 0.60
USP2 O75604 1/20 0.60
HSP90AA1 P07900 1/20 0.60
HSP90AB1 P08238 1/20 0.60
THRB P10828 1/20 0.60
G6PD P11413 1/20 0.60
ALOX15 P16050 1/20 0.60
CASP1 P29466 1/20 0.60
HSD17B10 Q99714 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CNR2 P34972 4/20 0.40
GAA P10253 2/20 0.38
NPC1 O15118 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.37
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17543522 0.87 MAPT (0.55) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL9616201 0.87 MAPT (0.55) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL23915318 0.85 ALDH1A1 (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL23915322 0.81 GAA (0.42) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL5563833 0.80 MAPT (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2564423 0.78 MAPT (0.52) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL30780916 0.78 MAPT (0.52) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL9467773 0.75 ALDH1A1 (1.00) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL7832979 0.74 MAPT (0.61) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL7834767 0.74 MAPT (0.61) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 MAPT 4876/4885ALDH1A1 944/4885MEN1 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.